Conservative initial postoperative anticoagulation strategy after HeartMate 3 left ventricular assist device implantation

被引:2
作者
Damman, Kevin [1 ]
van den Broek, Stan A. J. [1 ]
Mecozzi, Gianclaudio [2 ]
Droogh, Joep M. [3 ]
Metz, Ethel [3 ]
Lansink, Annemieke Oude [3 ]
Krikken, Jan A. [1 ]
Erasmus, Michiel E. [2 ]
Kuijpers, Michiel [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiothorac Surg, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Groningen, Netherlands
关键词
LVAD; HeartMate; 3; Anticoagulation;
D O I
10.1007/s12471-022-01671-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Although anticoagulation therapy is mandated after implantation of a left ventricular assist device (LVAD), postoperative bleedings and reoperations occur relatively frequently and are associated with worse outcomes. We evaluated the use of a conservative postoperative anticoagulation protocol in patients implanted with a HeartMate 3 (HM3) LVAD. Methods In a single-centre retrospective analysis of postoperative outcomes after HM3 LVAD implantation, a standard (old) anticoagulation protocol (i.e. early, full-dose anticoagulation with low-molecular weight heparin and overlapping vitamin K antagonist) was compared with a new conservative anticoagulation protocol (i.e. slow initiation of vitamin K antagonists without overlapping heparin). Main outcomes were changes in international normalised ratio (INR), lactate dehydrogenase (LDH), bleeding and/or tamponade events requiring reoperation, length of stay and adverse events. Results In total, 73 patients (48 in old vs 25 in new protocol group) were evaluated. Mean age was 56 years (standard deviation 13) and most patients (78%) were males. Changes in INR and LDH in the first 14 days were similar in both groups (p = 0.50 and p = 0.997 for interaction, respectively). Number of bleeding/tamponade events requiring reoperation was lower in the new than in the old protocol group (4% vs 33%, p = 0.005). Postoperative 30-day mortality was similar, and we observed no thromboembolic events. Median (25th-75th percentiles) total length of postoperative hospital stay (27 (25-41) vs 21 (19-27) days, p < 0.001) and length of intensive care unit stay (5 (2-9) vs 2 (2-5) days, p = 0.022) were significantly shorter in the new protocol group. Conclusion These retrospective data suggest that conservative slow initiation of anticoagulation therapy after HM3 LVAD implantation is associated with less bleeding/tamponade events requiring reoperation, a similar safety profile and a shorter duration of stay than the currently advised standard anticoagulation protocol.
引用
收藏
页码:466 / 472
页数:7
相关论文
共 50 条
  • [21] Gastrointestinal bleeding with the HeartMate II left ventricular assist device
    Morgan, Jeffrey A.
    Paone, Gaetano
    Nemeh, Hassan W.
    Henry, Scott E.
    Patel, Rosan
    Vavra, Jessica
    Williams, Celeste T.
    Lanfear, David E.
    Tita, Cristina
    Brewer, Robert J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (07) : 715 - 718
  • [22] Anti-factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation
    Feng, Iris
    Kurlansky, Paul A.
    Powley, Tanner R.
    Hynds, Melissa A.
    Yang, Christine G.
    Eisenberger, Andrew
    Hastie, Jonathan M.
    Sutherland, Lauren D.
    Yuzefpolskaya, Melana
    Colombo, Paolo C.
    Sayer, Gabriel T.
    Uriel, Nir Y.
    Naka, Yoshifumi
    Takeda, Koji
    ARTIFICIAL ORGANS, 2024, : 497 - 507
  • [23] First Pediatric HeartMate 3 Ventricular Assist Device Implantation in Romania - a Case Report
    Muntean, Iolanda
    Iurian, Diana-Ramona
    Nistor, Dan Octavian
    Barmou, Asmaa Carla
    Suciu, Horatiu
    JOURNAL OF CARDIOVASCULAR EMERGENCIES, 2024, 10 (01): : 48 - 53
  • [24] Late Bleeding and Neurological Sequelae After HeartMate II Left Ventricular Assist Device
    Najjar, Samer S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (09) : 889 - 890
  • [25] HeartMate 3 fully magnetically levitated left ventricular assist device for advanced heart failure - initial Serbian experience
    Nestorovic, Emilija
    Terzic, Dusko
    Putnik, Svetozar
    Ristic, Arsen
    Ristic, Miljko
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2018, 146 (9-10) : 584 - 587
  • [26] Implantation of the HeartWare Left Ventricular Assist Device
    Slaughter, Mark S.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2011, 23 (03) : 245 - 247
  • [27] HeartMate II left ventricular assist device;: early European experience
    Strueber, Martin
    Sander, Kare
    Lahpor, Jaap
    Ahn, Henrik
    Litzler, Pierre-Yves
    Drakos, Stavros G.
    Musumeci, Francesco
    Schtensak, Christian
    Friedrich, Ivar
    Gustafsson, Ronny
    Oertel, Frank
    Leprince, Pascal
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 34 (02) : 289 - 294
  • [28] Eptifibatide for the Treatment of HeartMate II Left Ventricular Assist Device Thrombosis
    Al-Quthami, Adeeb H.
    Jumean, Marwan
    Kociol, Robb
    Duc Thinh Pham
    Kiernan, Michael
    DeNofrio, David
    Kapur, Navin K.
    CIRCULATION-HEART FAILURE, 2012, 5 (04) : E68 - E70
  • [29] Postoperative bridging anticoagulation and left ventricular assist system thrombosis
    Nemer, David M.
    Stewart, Garrick C.
    Puligandla, Maneka
    Neuberg, Donna S.
    Givertz, Michael M.
    Mehra, Mandeep R.
    Couper, Gregory S.
    Connors, Jean M.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (01) : 57 - 66
  • [30] Postoperative Pulmonary Artery Pulsatility Index Improves Prediction of Right Ventricular Failure After Left Ventricular Assist Device Implantation
    Wei, Johnny
    Franke, Jack
    Kee, Abigail
    Dukes, Rachel
    Leonardo, Vincent
    Flynn, Brigid C.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2024, 38 (01) : 214 - 220